3B BlackBio DX Limited (formerly Kilpest India Limited) has received a regulatory disclosure from promoter Mahesh Kumar Upadhyay regarding the sale of equity shares under SEBI regulations. The transaction involved the disposal of 400 equity shares through open market operations conducted over two consecutive days in December 2025.

Transaction Details

The share sale was executed in two separate tranches, with 150 equity shares sold on December 23, 2025, and 250 equity shares sold on December 24, 2025. The disclosure was submitted to BSE Limited and the company on December 24, 2025, in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Changes

Prior to the transaction, Mahesh Kumar Upadhyay held 24,250 equity shares carrying voting rights in 3B BlackBio DX Limited. Following the sale of 400 shares, his holding reduced to 23,850 equity shares. The percentage shareholding remains at 0.28% of the company's total voting capital both before and after the transaction.

Company Capital Structure

The company's equity share capital structure remained unchanged following the transaction. 3B BlackBio DX Limited maintains its total equity share capital at ₹8.58 crores, comprising 85,82,670 equity shares with a face value of ₹10.00 each. The total diluted share capital also stands at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

The disclosure demonstrates adherence to SEBI's transparency requirements for substantial shareholding changes. Mahesh Kumar Upadhyay, identified as belonging to the promoter group, fulfilled his regulatory obligations by submitting the required documentation to both BSE Limited and the company's corporate relations department. The disclosure was signed by Whole Time Director Nikhil Kuber Dubey (DIN: 00538049) on behalf of the company.

3B BlackBio DX (formerly Kilpest India Limited) has reported strong financial results for the quarter ended September 30, 2025, with significant revenue growth and a major acquisition.

Financial Highlights

All figures in lakhs of rupees, except percentages

Revenue Growth

3B BlackBio DX reported a standalone revenue of 2,791.60 lakhs for the quarter, marking a significant increase of 37.1% compared to 2,035.70 lakhs in the previous quarter. This substantial growth in revenue indicates the company's strong market performance and increased sales.

Profitability

The company's standalone net profit showed impressive growth, increasing to 1,494.08 lakhs from 1,246.04 lakhs in the previous quarter. This represents a quarter-over-quarter growth of 19.9%.

Consolidated Performance

On a consolidated basis, 3B BlackBio DX reported a revenue of 3,890.21 lakhs for the quarter. This figure includes the performance of its newly acquired subsidiary, Coris Holding SRL, Belgium, from the acquisition date of August 29, 2025.

Business Segments

The company operates in two primary business segments:

1. Agrochemicals
2. Molecular Diagnostic Kits

Earnings Per Share

The basic earnings per share on a standalone basis was Rs 17.44 for the quarter, reflecting the company's strong profitability.

Strategic Acquisition

3B BlackBio DX completed the acquisition of Coris Holding SRL, Belgium on August 29, 2025. This strategic move is expected to enhance the company's product portfolio and international presence. The financial results of Coris Holding have been included in the consolidated figures from the acquisition date.

One-time Expenses

The company incurred one-time expenses of Rs 54.54 lakhs related to M&A advisory and due diligence for the Coris acquisition. These expenses reflect the company's investment in strategic growth through acquisitions.

Market Position

With its strong financial performance and recent acquisition, 3B BlackBio DX appears well-positioned in the molecular diagnostics and agrochemicals sectors. The significant revenue growth and strategic expansion demonstrate the company's current market strength.